Related Experiment Videos
Recurrent Clostridium difficile colitis. Tackling a tenacious nosocomial infection
Ann Marie Joyce1, David L Burns
1Lahey Clinic, Burlington, Massachusetts, USA.
Postgraduate Medicine
|December 5, 2002
Summary
Clostridioides difficile infection (CDI) recurs in 20% of patients, especially the elderly and those with colonic disease using antibiotics. Spore persistence complicates treatment, necessitating strategies to restore gut flora and prevent recurrence.
Area of Science:
- Infectious Diseases
- Microbiology
- Gastroenterology
Background:
- Clostridioides difficile infection (CDI) frequently recurs in hospitalized patients, posing a significant clinical challenge.
- Recurrence rates approach 20%, with high-risk groups including the elderly and individuals with pre-existing colonic conditions or recent antibiotic exposure.
Purpose of the Study:
- To review the epidemiology, diagnosis, and management of recurrent Clostridioides difficile infection.
- To highlight challenges in CDI treatment and explore emerging therapeutic strategies.
Main Methods:
- Literature review of studies on Clostridioides difficile infection recurrence.
- Analysis of diagnostic methods, including clinical suspicion and toxin detection via ELISA.
- Evaluation of current and developing treatment modalities.
Main Results:
- Key symptoms of CDI include diarrhea, abdominal pain, and leukocytosis.
- Diagnosis relies on clinical suspicion and stool toxin assays.
- Recurrence is attributed to persistent C. difficile spores, complicating eradication.
Conclusions:
- Effective first-line treatments include oral vancomycin or metronidazole for 10-14 days.
- Dose tapering over a month may aid spore destruction and normal flora regrowth.
- Probiotics (e.g., Lactobacillus GG, S. boulardii) and immunization are promising for preventing CDI and recurrence.